ATR and ovarian serous adenocarcinoma: In a recent phase 2 trial in platinum-resistant high-grade serous ovarian cancer, a combination of the selective ATR inhibitor berzosertib, and gemcitabine showed significantly prolonged progression-free survival compared to treatment with gemcitabine alone37.